Protease-Resistant IGFBP-3 Derivatives for IGF Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current approaches to modulating the insulin-like growth factor (IGF) signaling pathway for therapeutic purposes face challenges such as short half-life of recombinant IGF-I, undesired side effects, and reduced efficacy due to endogenous IGF binding proteins, particularly insulin-like growth factor binding protein 3 (IGFBP-3), which limits the effectiveness of IGF-I administration in treating various diseases.
Innovation Solution
Development of IGFBP-3 derivatives that are resistant to proteolytic cleavage and maintain binding affinities for IGF-I, IGF-II, and heparin similar to wild-type IGFBP-3, with options to enhance affinity, extend plasma half-life, and include fusion with immunoglobulin IgG1 Fc fragment or secreted alkaline phosphatase for therapeutic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If recombinant IGF-I is administered to treat diseases, then therapeutic efficacy is improved, but the half-life is short and side effects occur
Solution Approach 1:
The patent uses IGFBP-3 as an intermediary carrier protein to deliver IGF-I. The IGFBP-3/IGF-I complex circulates in the bloodstream, protecting IGF-I from rapid clearance and proteolytic degradation. This mediator approach extends the half-life of IGF-I from minutes to hours, while the complex gradually releases IGF-I to maintain therapeutic efficacy.
Solution Approach 2:
The invention creates a composite therapeutic system consisting of IGFBP-3 and IGF-I forming a stable complex. This composite structure combines the long circulation half-life of IGFBP-3 with the high biological activity of IGF-I, achieving both extended duration of action and sustained therapeutic efficacy simultaneously.
2Duration of action of moving object
If IGFBP-3 is used to deliver IGF-I, then half-life is extended, but proteolytic cleavage reduces efficacy
Solution Approach 1:
The patent extracts and replaces the vulnerable intermediate domain of IGFBP-3 with a protease-resistant linker sequence. This removal of the cleavage-prone region eliminates the weakness in the molecule while preserving the essential N-terminal and C-terminal domains that are responsible for IGF binding and biological activity.
Solution Approach 2:
The invention changes the proteolytic stability parameter of IGFBP-3 by modifying its amino acid sequence in the intermediate domain. The engineered linker has resistance to proteolytic enzymes, transforming the molecule from being easily degraded to being stable in circulation, thereby maintaining therapeutic efficacy over extended periods.
3Reliability
If endogenous IGFBP-3 is present, then IGF-I circulation is regulated, but binding affinity is reduced due to competition
Solution Approach 1:
The patent employs exogenous IGFBP-3/IGF-I complexes as a preliminary delivery system that saturates endogenous IGFBP binding sites before IGF-I can be sequestered by endogenous IGFBP-3. This preliminary occupation of binding sites ensures that administered IGF-I remains available for receptor interaction, overcoming the competitive inhibition by endogenous proteins.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These derivatives provide sustained IGF delivery, reduce side effects, and enhance therapeutic efficacy in treating conditions like cancer, diabetes, muscle wasting diseases, and proliferative retinopathies by effectively regulating the IGF signaling pathway.
Implementation Method 1
IGFBP-3 derivatives that are resistant to proteolytic cleavage and maintain binding affinities for IGF-I, IGF-II, and heparin similar to wild-type IGFBP-3
Data Source
Figure 1
Figure 2A~2B
Figure 3
AI summary
The present invention provides polypeptide derivatives of IGFBP-3 that are resistant to proteolytic cleavage. These IGFBP-3 derivatives are useful in a variety of therapeutic and diagnostic applications. Also provided are pharmaceutical compositions and kits comprising such IGFBP-3 derivatives and methods for using these derivatives for the treatment of a variety of disorders.